Table 2.
Antimicrobial susceptibility pattern of C. difficile isolates (n = 71).
| Antimicrobial agent | MIC range (mg/L) | MIC breakpoint criteria (mg/L) | Frequency (%) | |||||
|---|---|---|---|---|---|---|---|---|
| S | I | R | ECOFF | S | I | R | ||
| Vancomycina | 0.125–0.5 | ≤2 | ≥4 | 71 (100) | – | 0 (0) | ||
| Metronidazolea | 0.016–256 | ≤8 | 16 | ≥32 | 68 (95.8) | 0 (0) | 3 (4.2) | |
| Clindamycina | 0.023–256 | ≤2 | 4 | ≥8 | 13 (18.3) | 1 (1.4) | 57 (80.3) | |
| Cefriaxonea | 0.064–256 | ≤16 | 32 | ≥64 | 22 (31.0) | 13 (18.3) | 36 (50.7) | |
| Erythromycina | 0.094–256 | ≤2 | 4 | ≥8 | 8 (11.3) | – | 63 (88.7) | |
| Rifampicinb | 0.002–32 | 0.004 | 6 (85.0) | – | 65 (91.5) | |||
| Ciprofloxacina* | 0.064–32 | ≤2 | 4 | ≥8 | 10 (14.1) | 2 (2.8) | 59 (83.1) | |
| Tetracyclinea | 0.016–32 | ≤4 | 8 | ≥16 | 35 (49.3) | 29 (40.8) | 7 (9.9) | |
aBreakpoints per CLSI MIC values for anaerobes. bBreakpoints per EUCAST MIC guidelines for C. difficile. *The Moxifloxacin breakpoint is used as a proxy. MIC, minimum inhibitory concentration; S, susceptible; I, intermediate; R, resistant; ECOFF, epidemiological cut-off value.